er Maersk Q2 EBITDA & revs inline, raising FY guidance, mainly in Maersk line EFTA00406719 (trading +1.0%) Astrazeneca ups guidance after selling Nexium rights to Pfizer, ups guidance (trading +0.70%) Salzgitter Q2 inline (post profit warning June 26th), leaves outlook unchanged (trading +1.5%) Me